Taysha Gene Therapies, Inc., a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN1 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 foe the treatment of for SLC13A5 Deficiency; and TSHA-101 for the treatment of GM2 gangliosidosis. Taysha Gene Therapies, Inc. has a strategic partnership with The University of Texas Southwestern Medical Center to develop and commercialize transformative gene therapy treatments. The company was incorporated in 2019 and is based in Dallas, Texas.
P/E ratio for Taysha Gene Therapies, Inc. (TSHA)
P/E ratio as of 2023: -1.84
According to Taysha Gene Therapies, Inc.'s latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is -1.84. At the end of 2022 the company had a P/E ratio of -0.59.
P/E ratio history for Taysha Gene Therapies, Inc. from 2019 to 2023
PE ratio at the end of each year
| Year | P/E ratio |
|---|---|
| 2023 | -1.84 |
| 2022 | -0.59 |
| 2021 | -2.50 |
| 2020 | -10.90 |
| 2019 | -798.24 |